XENE Xenon Pharmaceuticals Inc.
$36.01▲ +0.67%
Healthcare
Other
Volume 1.08M
Avg Volume (10D) 1.16M
Key Metrics & Fundamentals
Market Cap
$3.49B
P/E Ratio
–
Div Yield
0.00%
52W Range
33.38 - 72.66
% vs 50 MA
-23.10%
% vs 200 MA
-31.31%
RSI-14
37.1
MACD Histogram
+0.9100
Beta (1Y vs SPY)
0.82
Free Cash Flow
-$95.67M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$122.29M
COGS
–
Operating Exp
$123.16M
Operating Income
-$123.16M
EBIT
-$123.16M
Pretax Income
-$111.32M
Net Income
-$110.74M
EPS (Diluted)
-1.11
Price & Volume History
Loading chart…
Recent News
Inside the $1 Billion Blockbuster Opportunity Sending Rapport Therapeutics Stock Higher
Barrons.com · Oct 20, 2026 3:46 PM ET
XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?
Zacks · Oct 15, 2026 12:05 PM ET
Why Xenon Pharmaceuticals (XENE) Is Getting Attention Now
Simply Wall St. · Oct 9, 2026 7:10 PM ET
Xenon Pharmaceuticals (XENE) Stock May Still Look Above Fair Value On Its Research Pipeline
Simply Wall St. · Oct 9, 2026 10:14 AM ET
Insiders Are Buying These 2 ‘Strong Buy’ Stocks With Over 60% Upside
TipRanks · Oct 7, 2026 1:57 PM ET
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 2, 2026 4:01 PM ET
Xenon’s Insider Buying Tops $1.6M – XENE Stock Heads For Best Day In Over Month
Stocktwits · Oct 1, 2026 12:10 PM ET
Xenon's AZK Approval Path Unlikely to Be Hurt by Safety Issues, RBC Says
MT Newswires · Oct 1, 2026 11:02 AM ET
Xenon Pharmaceuticals Insider Bought Shares Worth $1,121,400, According to a Recent SEC Filing
MT Newswires · Oct 1, 2026 9:23 AM ET
Ian Mortimer Receives the 2026 Bloom Burton Award
TMX Newsfile · Sep 29, 2026 8:00 AM ET
Financial Overview - Income Statement
Quarterly
Mar 2025
See XENE's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.